Load Incorporating Cardiac Assessment by Echocardiography In Patients With SEpsis (LIAISE Study) (LIAISE)
Load Incorporating Cardiac Assessment by Echocardiography In Patients With SEpsis: a Prospective Observational Study (LIAISE Study)
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Detaillierte Beschreibung
Background Sepsis is a global killer, whereby an infection spreads throughout the body via the bloodstream. It often leads to lethal heart damage, "septic cardiomyopathy", with mortality rates for those affected soaring above 40%. To facilitate early and appropriate intervention for damaged hearts and improve their outcomes, accurate assessment of heart function, and proper prediction of their adverse events are crucial. However, conventional cardiac assessments cannot capture heart dysfunction accurately since they have a significant limitation called "load-dependency", which means these parameters' values are affected by loading conditions on the heart, such as blood pressure and circulating blood volume. In sepsis, as these loads on the heart dramatically change minute by minute, the values of cardiac assessment also fluctuate and frequently underestimates heart damage, failing to properly predict their adverse events. To address this, novel load-incorporating echocardiographic parameters can capture heart function more accurately regardless of these hemodynamic conditions, and previous data has demonstrated its better predictive value in cardiogenic shock cases where loading conditions similarly fluctuate. As a next step, this study seeks to elucidate their utility in patients with sepsis.
Aims
- To investigate if novel load-incorporating echocardiography can predict adverse events more accurately than conventional parameters in adult patients with sepsis presenting to intensive care units (ICUs).
- To identify the most sensitive cardiac parameter to predict adverse events in sepsis, from comprehensively collected cardiac parameters along with novel-incorporating echocardiography.
Hypothesis Load-incorporating echocardiographic parameters will be more accurate in predicting the incidence of adverse events within 30 days after ICU admission than conventional echocardiographic parameters.
Outcomes Primary outcome The incidence of all-cause death for 30 days after ICU admission
Secondary outcomes
- Incidence of and time to all-cause death or cardiovascular readmission for 1 year after ICU admission
- Incidence and duration of mechanical circulatory support, mechanical ventilation, renal replacement therapy, and vasoactive agent therapy during initial admission.
- Reversibility of cardiac function (LVEF increases ≥ 5% in echo 3-5 days after ICU admission)
- Sequential Organ Failure Assessment (SOFA) score at 3 days after ICU admission
Studientyp
Studientyp
Einschreibung (Geschätzt)
Einschreibung
Kontakte und Standorte
Studienkontakt
Studienkontakt
- Name: Hideaki Nonaka, Dr
- Telefonnummer: +61 449967910
- E-Mail: hideaki54nonaka@gmail.com
Studieren Sie die Kontaktsicherung
- Name: Nonaka
Studienorte
-
-
Queensland
-
Chermside, Queensland, Australien, 4032
- The Prince Charles Hospital
-
Kontakt:
- Hideaki Nonaka, Dr
- Telefonnummer: +61 449967910
- E-Mail: hideaki54nonaka@gmail.com
-
Kontakt:
- Nonaka
-
-
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
- Erwachsene
- Älterer Erwachsener
Akzeptiert gesunde Freiwillige
Probenahmeverfahren
Studienpopulation
Beschreibung
Inclusion Criteria:
- Adults ≥ 18 years old.
- Clinically suspected of defined sepsis
- Sepsis-induced hypotension or hypoperfusion (arterial or venous blood lactate ≥2.0 mmol/L OR mean artery pressure ≤65 mmHg over 30 mins OR at least one vasoactive or inotropic agent administered).
- At least one dose of an IV antimicrobial has been commenced.
Exclusion Criteria:
- Suspected or confirmed pregnancy.
- Any severe concomitant diseases with limited life expectancy <30 days.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
Anzahl der Gruppen / Kohorten
Kohorten und Interventionen
Gruppe / KohorteGruppe / Kohorte |
|---|
|
Sepsis with hypotension or signs of hypoperfusion admitted to ICU
|
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
|---|---|
|
All cause death
Zeitfenster: Day 30 after ICU admission
|
Day 30 after ICU admission
|
Sekundäre Ergebnismessungen
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
All cause death and adverse cardiac event readmission
Zeitfenster: 1 year after ICU admission
|
Incidence of and time to all-cause death or adverse cardiac event readmissions for 1 year after ICU admission
|
1 year after ICU admission
|
|
Mechanical circulartory suport, mechanical ventilation, renal replacement therapy, and vasoactive/inotropic agent therapy
Zeitfenster: during the initial index admission, between Day 0 and Day 30
|
Incidence and duration (days) of mechanical circulatory support, mechanical ventilation, renal replacement therapy, and vasoactive agent therapy during initial admission
|
during the initial index admission, between Day 0 and Day 30
|
|
Reversibility of cardiac function
Zeitfenster: Day 3 to Day 5
|
Left ventricular ejection fraction increases ≥ 5% in echo from 3-5 days after ICU admission
|
Day 3 to Day 5
|
|
Sequential Organ Failure Assessment score at 3 days after ICU admission
Zeitfenster: at Day 3 of ICU admission
|
Sequential Organ Failure Assessment score at Day 3 of index ICU admission will be assessed on a scale from 0 to 24, with higher scores indicating more severe organ failure.
|
at Day 3 of ICU admission
|
Andere Ergebnismessungen
Andere Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
lengh of hosiptal or ICU stay
Zeitfenster: during the initial index admission, between Day 0 and Day 30
|
during the initial index admission, between Day 0 and Day 30
|
|
|
In-hospital mortariy
Zeitfenster: during the initial index admission, between Day 0 and Day 30
|
during the initial index admission, between Day 0 and Day 30
|
|
|
Vasoactive-inotropic score at 24, and 48 hours
Zeitfenster: at 24 hour and 48 hour of index ICU admission
|
at 24 hour and 48 hour of index ICU admission
|
|
|
Amount of fluid administered for the first 24 hours in ICU admission
Zeitfenster: Day 1 of index ICU admission
|
CSL
|
Day 1 of index ICU admission
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Mitarbeiter
Mitarbeiter
Ermittler
Ermittler
- Studienleiter: Hideaki Nonaka, Dr, The University of Queensland
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Geschätzt)
Studienbeginn
Primärer Abschluss (Geschätzt)
Primärer Abschluss
Studienabschluss (Geschätzt)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- 2025/PR011848
- INN2024-16 (Andere Zuschuss-/Finanzierungsnummer: The Prince Charles Hospital Foundation (The Common Good))
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
IPD-Sharing-Zeitrahmen
IPD-Sharing-Zugriffskriterien
Art der unterstützenden IPD-Freigabeinformationen
- STUDIENPROTOKOLL
- SAFT
- ICF
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .